Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium

Clin Infect Dis. 1999 Aug;29(2):361-6. doi: 10.1086/520216.

Abstract

In a prospective observational cohort study designed to assess the role of oral bacitracin solution plus doxycycline in the eradication of intestinal carriage of vancomycin-resistant Enterococcus faecium (VREF) in patients on a renal ward, rectal swab specimens were obtained from 15 treated and 24 control patients. Cultures of the rectal swabs were negative for 15 (100%) of the antibiotic-treated vs. eight (33.3%) of the untreated patients (P < .001) on day 14. However, follow-up for a mean of 127 and 130 days revealed 9 of 15 (60%) and 15 of 24 (62.5%) in the treated and untreated cohorts (P = .86), respectively, carried VREF intermittently or persistently. Quantitative VREF stool cultures in the treated cohort revealed an initial 3.1-log10/g decrease, but there was an increase to pretreatment levels at 2-4 and 5-7 weeks post-treatment (7.8 and 7.4 log10/g). Oral bacitracin and doxycycline were not efficacious in reducing the carriage of VREF beyond the 2-week interval during which they were given.

MeSH terms

  • Administration, Oral
  • Anti-Bacterial Agents / therapeutic use*
  • Bacitracin / therapeutic use*
  • Doxycycline / therapeutic use*
  • Drug Resistance, Microbial
  • Drug Therapy, Combination
  • Enterococcus faecium / drug effects
  • Enterococcus faecium / growth & development*
  • Feces / microbiology
  • Female
  • Follow-Up Studies
  • Gram-Positive Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / microbiology*
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Prospective Studies
  • Vancomycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Bacitracin
  • Vancomycin
  • Doxycycline